DK0934526T3 - Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål - Google Patents

Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål

Info

Publication number
DK0934526T3
DK0934526T3 DK97943221T DK97943221T DK0934526T3 DK 0934526 T3 DK0934526 T3 DK 0934526T3 DK 97943221 T DK97943221 T DK 97943221T DK 97943221 T DK97943221 T DK 97943221T DK 0934526 T3 DK0934526 T3 DK 0934526T3
Authority
DK
Denmark
Prior art keywords
target
proteins
peptides
methods
specific affinity
Prior art date
Application number
DK97943221T
Other languages
English (en)
Inventor
Ton Logtenberg
Kruif Cornelis Adriaan De
Original Assignee
Bisys B V U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bisys B V U filed Critical Bisys B V U
Application granted granted Critical
Publication of DK0934526T3 publication Critical patent/DK0934526T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DK97943221T 1996-10-08 1997-10-07 Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål DK0934526T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202791 1996-10-08
PCT/NL1997/000557 WO1998015833A1 (en) 1996-10-08 1997-10-07 Methods and means for selecting peptides and proteins having specific affinity for a target

Publications (1)

Publication Number Publication Date
DK0934526T3 true DK0934526T3 (da) 2003-05-05

Family

ID=8224468

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97943221T DK0934526T3 (da) 1996-10-08 1997-10-07 Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål

Country Status (9)

Country Link
EP (1) EP0934526B1 (da)
JP (1) JP2001512560A (da)
AT (1) ATE230850T1 (da)
AU (1) AU4474497A (da)
CA (1) CA2267139A1 (da)
DE (1) DE69718341T2 (da)
DK (1) DK0934526T3 (da)
ES (1) ES2190543T3 (da)
WO (1) WO1998015833A1 (da)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2338865A1 (en) * 1997-07-29 1999-02-11 James S. Huston Methods for detecting binding events using multiple binding partners and muliple targets
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
DE19802576B4 (de) * 1998-01-23 2004-10-28 Xerion Pharmaceuticals Ag Verfahren zur gleichzeitigen Identifizierung von Proteinen und ihren Bindungspartnern
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL144559A0 (en) 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
AU778776B2 (en) 1999-04-14 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The High sensitivity phage display biomolecule detection
EP1684077A1 (en) * 1999-05-14 2006-07-26 McGill University Method for identifying modulators of interacting proteins
DE60025480T2 (de) * 1999-05-14 2006-08-24 Mcgill University, Montreal Methoden zur identifizierung von modulatoren wechselwirkender proteine
EP1245955A4 (en) * 1999-12-27 2004-06-16 Toray Industries CYTOKINE TYPE PEPTIDE
ES2282797T3 (es) * 1999-12-27 2007-10-16 Crucell Holland B.V. Anticuerpo monoclonal humano que une ep-cam y su uso en la terapia delcancer.
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
SE0000597D0 (sv) * 2000-02-24 2000-02-24 Active Biotech Ab Novel antibody
EP1130099A1 (en) * 2000-02-25 2001-09-05 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
AU2001241264A1 (en) * 2000-02-25 2001-09-03 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
DE60117781T2 (de) 2000-04-21 2006-11-23 Amgen Inc., Thousand Oaks Peptidderivate des apolipoproteins-a1/aii
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP1174440A1 (en) * 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
DE60136816D1 (de) 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
FR2821856B1 (fr) * 2001-03-09 2003-12-26 Didier Elmlinger Procede de criblage croise d'une banque d'expression d'adn et d'une banque de molecules cibles isolees sur un support permettant la comparaison simultanee de l'affinite et la selectivite de leurs interactions
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
PT2000545E (pt) 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
US20040241688A1 (en) * 2001-07-19 2004-12-02 Cuneyt Bukusoglu Human tissue specific drug screening procedure
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
DE60332483D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
DK2295073T3 (da) 2003-11-17 2014-07-28 Genentech Inc Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
AU2011218688B2 (en) * 2004-05-27 2013-01-10 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
EP2314620B1 (en) 2004-05-27 2013-06-05 Crucell Holland B.V. Method of identifying binding molecules capable of neutralizing rabies virus
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
WO2006062776A2 (en) 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2622603C (en) 2005-09-15 2014-06-17 Crucell Holland B.V. Method for preparing immunoglobulin libraries
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
DK2005185T3 (da) 2006-03-22 2011-01-31 Viral Logic Systems Technology Corp Fremgangsmåde til identifikation af polypeptidtargets
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2881717C (en) 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
SI2059532T1 (sl) 2006-09-07 2013-04-30 Crucell Holland B.V. Humane vezne molekule, ki so zmoĹľne nevtralizirati virus influence H5N1 in njihove uporabe
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
JP5410985B2 (ja) 2006-12-05 2014-02-05 クルセル ホランド ベー ヴェー 液体抗狂犬病抗体製剤
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2617827A1 (en) 2007-03-26 2013-07-24 Celexion, LLC Method for displaying engineered proteins on a cell surface
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CN102459591B (zh) 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
PH12012500982A1 (en) 2009-11-30 2019-07-10 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
MA34057B1 (fr) 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
GB2503604B (en) 2011-03-21 2020-04-22 Biodesy Llc Classification of kinase inhibitors using second harmonic optical techniques
CA2836503C (en) 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
JP2015506944A (ja) 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Ｆｇｆ１９修飾薬を使用する方法
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
JP2015511598A (ja) 2012-03-16 2015-04-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
RU2014141617A (ru) 2012-03-16 2016-05-10 Дженентек, Инк. Сконструированные конформационно-стабилизированные белки
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
GB2517857A (en) 2012-04-25 2015-03-04 Biodesy Inc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN105247050B (zh) 2013-03-14 2020-06-16 天演药业 用于文库构建、亲和力结合剂筛选和其表达的整合系统
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
RU2016144405A (ru) 2014-05-23 2018-06-26 Дженентек, Инк. MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
WO2016172485A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
US11485736B2 (en) 2018-12-20 2022-11-01 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
BR112021021673A2 (pt) 2019-05-09 2021-12-21 Genentech Inc Método para melhorar o emparelhamento preferencial de uma cadeia pesada e uma cadeia leve de um anticorpo e anticorpo
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
WO2023066881A1 (en) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes
TW202448509A (zh) 2023-05-12 2024-12-16 美商建南德克公司 減少抗體黏度之方法及組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3242402B2 (ja) * 1990-11-07 2001-12-25 アボット・ラボラトリーズ Ｃ型肝炎ウイルスに対するモノクローナル抗体およびその使用法
EP1820858B1 (en) * 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
WO1995015982A2 (en) * 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
SE9401650D0 (sv) * 1994-05-11 1994-05-11 Lars Frykberg Nytt sätt att identifiera peptider samt hjälpmedel som kan användas vid sättet

Also Published As

Publication number Publication date
ES2190543T3 (es) 2003-08-01
EP0934526B1 (en) 2003-01-08
AU4474497A (en) 1998-05-05
JP2001512560A (ja) 2001-08-21
CA2267139A1 (en) 1998-04-16
DE69718341D1 (de) 2003-02-13
DE69718341T2 (de) 2003-10-30
ATE230850T1 (de) 2003-01-15
EP0934526A1 (en) 1999-08-11
WO1998015833A1 (en) 1998-04-16

Similar Documents

Publication Publication Date Title
DK0934526T3 (da) Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
ATE332368T1 (de) Selektion von proteinen mittels rns-protein fusionen
GB2338237A (en) In vitro peptide or protein expression library
ATE406439T1 (de) Eukaryontische signalsequenzen für polypeptid- expressions- und polypeptid- präsentationsbibliotheken
DE69738670D1 (de) Verfahren zur oligomerisation von peptiden
NO20031049L (no) Syntetiske erytropoese-stimulerende proteiner
CY1110699T1 (el) Μεθοδος πισοτοποιησης πεδιων θεσης συνδεσης που διατηρουν την ικανοτητα συνδεσης προς εναν επιτοπο
ATE282631T1 (de) Sh3-bindender peptide von cortactin und deren verwendung
DK1124568T3 (da) Polyspecifikke bindingsmolekyler og anvendelser deraf
DK0877760T3 (da) MHC-kpmplekser og anvendelse deraf
WO2004065416A3 (en) Synthetic antibody phage libraries
CY1112101T1 (el) Νευροτροφικοι παραγοντες
NO20000934L (no) Adipocyttspesifikke proteinhomologer
DE60335000D1 (de) In vitro peptid-expressionsbank
DE69535829D1 (de) Verbesserung in bezug auf bindungsproteine bei der erkennung von dna
DK2202308T3 (da) Fremgangsmåder og sammensætninger til manipulation af polypeptider
DE59708952D1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
ATE327328T1 (de) Adipozyten-spezifische protein homologe
EP2305710A3 (en) Synthetic antibody phage libraries
EP0772773A4 (en) Src SH3 BINDING PEPTIDES AND METHOD FOR THEIR INSULATION AND USE
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO1999030165A3 (en) Processes for identifying a solvent condition suitable for determining a biophysical property of a protein
WO2004018619A3 (en) P53 binding t cell receptor molecules and uses thereof
EP1027070A4 (en) CONJUGATES FROM HEAT SHOCK PROTEIN-BINDING PEPTIDES